Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins
Authors:
- Varvara MaksimovaVMVarvara Maksimova
- Valeriia PopovaVPValeriia Popova
- Anzhelika PrusAPAnzhelika Prus
- Evgeniya LylovaELEvgeniya Lylova
- Olga UsalkaOUOlga Usalka
- Guzel SagitovaGSGuzel Sagitova
- Ekaterina ZhidkovaEZEkaterina Zhidkova
- Julia MakusJMJulia Makus
- Ekaterina TrapeznikovaETEkaterina Trapeznikova
- Gennady BelitskyGBGennady Belitsky
- Marianna YakubovskayaMYMarianna Yakubovskaya
- Kirill KirsanovKKKirill Kirsanov
Open Access
- 17 August 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12874
Abstract
The development of malignant tumors is caused by a complex combination of genetic mutations and epigenetic alterations, the latter of which are induced by either external environmental factors or signaling disruption following genetic mutations. Some types of cancer demonstrate a significant increase in epigenetic enzymes, and targeting these epigenetic alterations represents a compelling strategy to reverse cell transcriptome to the normal state, improving chemotherapy response. Curaxin CBL0137 is a new potent anticancer drug that has been shown to activate epigenetically silenced genes. However, its detailed effects on the enzymes of the epigenetic system of transcription regulation have not been studied. Here, we report that CBL0137 inhibits the expression of DNA methyltransferase DNMT3a in HeLa TI cells, both at the level of mRNA and protein, and it decreases the level of integral DNA methylation in Ca Ski cells. For the first time, it is shown that CBL0137 decreases the level of BET family proteins, BRD2, BRD3, and BRD4, the key participants in transcription elongation, followed by the corresponding gene expression enhancement. Furthermore, we demonstrate that CBL0137 does not affect the mechanisms of histone acetylation and methylation. The ability of CBL0137 to suppress DNMT3A and BET family proteins should be taken into consideration when combined chemotherapy is applied. Our data demonstrate the potential of CBL0137 to be used in the therapy of tumors with corresponding aberrant epigenetic profiles.Keywords
Funding Information
- Russian Science Foundation (21-75-10163)
This publication has 49 references indexed in Scilit:
- The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer EffectsClinical Cancer Research, 2016
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatinNature Structural & Molecular Biology, 2016
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACTScience Translational Medicine, 2011
- Trichloroacetic Acid (TCA) Precipitation of ProteinsCold Spring Harbor Protocols, 2011
- Identification of a Functional Network of Human Epigenetic Silencing FactorsJournal of Biological Chemistry, 2010
- 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysisBone Marrow Transplantation, 2009
- High-throughput DNA methylation profiling using universal bead arraysGenome Research, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- The Bradford Method for Protein Quantitation1994